Breaking News

Recipharm Expands Analytical Development Services

December 4, 2012

Adds significant capacity at Solna facility

Recipharm has made a strategic investment to expand capacity for analytical services and stability studies at its facility in Solna, Sweden. The facility, which is equipped with advanced labs for pharmaceutical formulation and a GMP suite for development and manufacture of sterile and non-sterile clinical trial materials, will be reconstructed to facilitate the expansion of analytical development.
 
Analytical services will include: development and validation of stability indicating analytical methods, supply and execution of method transfer protocols, establishment of new product assay and degradation methods, graduated validation plans, cleaning validation, report writing and stability studies according to ICH. The company anticipates that the analytical lab in Solna will be ready and compliant with ICH, EU and FDA GMP in May 2013.
 
“This is a very important step for us as increasing this capacity will enable the company to enhance the high quality services to our customers,” said Maria Lundberg, general manager at Recipharm Pharmaceutical Development. “Our analytical development service is already an integrated and vital part of the pharmaceutical development work, and this investment will enable our business to continue to grow, creating more flexibility and a better service offering. We are convinced that it is vital to small and large pharma companies that competent service partners can supply high quality pharmaceutical development services including high quality analytical development.”

Related Contract Manufacturing:

Related Compliance:

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements